Emergent BioSolutions Delivers over 3 Million Doses of BioThrax(R) to U.S. Department of Health and Human Services for Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has successfully completed the 4Q 2006 deliveries of over three million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA...
Emergent BioSolutions Celebrates Initial Public Offering; CEO To Ring Opening Bell on the NYSE
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company that develops vaccines and therapeutics for biodefense and commercial applications and manufactures the only anthrax vaccine...
Emergent BioSolutions Announces Pricing of Its Initial Public Offering
Emergent BioSolutions Inc. (NYSE:EBS) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $12.50 per share. All of these shares are being...
Emergent BioSolutions Awarded Two Grants From NIAID To Support Development Of Anthrax Immune Globulin Therapeutic
Emergent BioSolutions Inc., a privately held biopharmaceutical company, today announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases (NIAID)...
U.S. Department Of Homeland Security Certifies BioThrax® (Anthrax Vaccine Adsorbed) As An Approved Product For Homeland Security
Emergent BioSolutions Inc., a privately held biopharmaceutical company, today announced that the United States Department of Homeland Security (DHS) has granted the company's application for...
Emergent BioSolutions Inc. Files Registration Statement For Proposed Initial Public Offering
Emergent BioSolutions Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission related to the proposed initial public offering of its common...
Emergent BioSolutions Expands Presence In Germany
Emergent BioSolutions Inc., a privately held biopharmaceutical company, today announced it has completed the acquisition of Vivacs GmbH, a privately held biotechnology company based in Munich,...
Cornerstone Ceremony Welcomes New Vaccine Production Facility To Michigan
Emergent BioSolutions, a biopharmaceutical company, announced today the dedication of a new large-scale vaccine production facility for its BioDefense Operations in a gala ceremony on its Lansing,...
Joe M. Allbaugh, Former FEMA Director, Joins Emergent BioSolutions’ Board Of Directors
Emergent BioSolutions today announced that Joe M. Allbaugh, who served as the Director of the Federal Emergency Management Agency (FEMA) under President George W. Bush from 2001 to 2003, has joined...
Former DHHS Secretary, Dr. Louis W. Sullivan, Joins Board Of Directors Of Emergent BioSolutions
Emergent BioSolutions Inc., a privately-held biopharmaceutical company, announced today that Louis W. Sullivan, M.D. has been named to its Board of Directors. A physician, academician, and public...
Emergent BioSolutions Signs Agreement with sanofi pasteur for Development of Novel Meningitis B Vaccine
Emergent BioSolutions Inc, a privately-held biopharmaceutical company, today announced it has signed an agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN...
DHHS Expands Emergent BioSolutions’ Contract To Supply BioThrax To The Strategic National Stockpile
Emergent BioSolutions Inc. today announced that the Department of Health and Human Services has modified its contract and is purchasing an additional five million doses of BioThrax®, the only...